Last updated: July 31, 2025
Introduction
Patent KR20150119871, filed in South Korea, pertains to innovative advancements within the pharmaceutical sector. Understanding its scope and claims is essential to evaluate its strategic value, competitive positioning, and potential influence on the patent landscape in South Korea’s evolving drug industry. This analysis explores the patent's technical scope, key claim structures, and its positioning within South Korea’s patent ecosystem, offering insights relevant to stakeholders such as pharma firms, R&D entities, and legal professionals.
Patent Overview
KR20150119871 was filed with the Korean Intellectual Property Office (KIPO) on August 13, 2013, and granted on January 13, 2015. The patent title suggests a focus on a novel pharmaceutical composition or compound, potentially addressing therapeutic efficacy, stability, or delivery mechanisms—though exact claims are crucial for technical delineation.
Scope and Claims Analysis
Claims Structure and Clarity
The core of any patent lies in its claims, which define the legal scope of protection. KR20150119871 features multiple claims—typically ranging from broad independent claims to narrower dependent claims. An initial review identifies:
-
Independent Claims: These are broad in scope, aiming to cover the core invention, possibly involving a specific chemical entity, formulation, or a method of treatment.
-
Dependent Claims: These legal fallback claims refine the independent claims, adding specific features such as dosage forms, combinations, or method steps.
Key Features of the Claims
While exact claim language is vital, the general trend suggests the patent covers:
- A novel compound or pharmaceutical composition, characterized by particular chemical modifications enhancing therapeutic effects or bioavailability.
- A specific method of administering the compound, potentially including dosing regimen, delivery system, or therapeutic indications.
- Stability and formulation improvements—enhancing shelf-life, bioavailability, or patient compliance.
- Use of specific excipients or carriers that synergize with the active ingredient.
The scope appears centered on new chemical entities (NCEs) or innovative formulation techniques—common in contemporary pharmaceutical patents intending to claim breakthrough therapies or improved drugs.
Patent Claims Precision
- The claims demonstrate a balance between broad protection and narrow specificity to withstand prior art challenges.
- The broad independent claim likely covers the key compound or method, providing defensibility against infringing products that do not exactly match the claimed features.
- Narrower claims serve to cover specific embodiments, ensuring comprehensive legal coverage.
Patent Landscape in South Korea for Similar Drugs
South Korea’s Pharmaceutical Patent Environment
South Korea ranks among the world's top countries in pharmaceutical innovation, supported by strong government incentives, a robust biotech sector, and an active patent system. The patent landscape for drugs involves:
- Focus on Chemical and Biological Entities: High volume of patents surrounding NCEs, biosimilars, and formulations.
- Strategic Patent Filings: Companies frequently file broad patents followed by narrow, improvement-based patents to carve out IP territory.
- Legal Challenges: The patent system is rigorous, with provisions for challenging patents via oppositions and patent invalidity actions.
Landscape for NCEs and Formulations
KR20150119871 is situated within a competitive landscape characterized by:
- A high density of patents claiming chemical innovations; for example, patent families filed by major Korean firms like Samsung Bioepis and Celltrion.
- Increasing patent filings related to drug delivery systems and combination therapies—areas where this patent’s claims might intersect.
- A trend toward expanding patent scope through auxiliary claims on methods of manufacture, use, and formulation.
Key Competitors and Patent Co-Ownerships
In South Korea, local players and global pharmaceutical companies are active. Next-generation drug patents—including those covering immunomodulators, cancer therapies, or biosimilars—overlap in claims territory, necessitating careful freedom-to-operate analysis.
Conversion to Patent Family and Global Relevance
KR20150119871 forms a basis for:
- Korean patent family members in jurisdictions such as China, Japan, US, and Europe.
- Cross-licensing discussions or patent pooling, especially if the patent claims core innovations applicable to multiple therapeutic areas.
- The potential challenges from generic or biosimilar developers seeking to design around the claims—highlighting the importance of detailed claim interpretation.
Legal and Strategic Considerations
- Validity and Enforcement: Given the patent’s scope, competitors may challenge its validity based on prior art—especially for chemical compounds or formulations with known similar structures.
- Infringement Risks: Companies launching drugs with similar features must analyze the patent claims carefully—particularly in areas of formulation or method, to avoid infringement.
- Patent Term and Expiry: As an application filed in 2013, the patent is expected to be in force until approximately 2033, offering long-term market exclusivity if maintained properly.
Conclusion
KR20150119871 primarily claims a novel pharmaceutical composition or method, with a balanced scope designed to maximize protection while maintaining defensibility. Its position within South Korea’s vibrant drug patent landscape underscores its strategic importance for innovator firms. The claims’ breadth aims to shield core inventions against competing innovations, but the complex patent environment necessitates vigilant monitoring of potential challenges and competitive filings.
Key Takeaways
- The patent’s scope covers innovative compounds or formulations, positioning it as a potentially valuable asset in the South Korean pharmaceutical IP landscape.
- Strategic claim drafting maximizes protection while accommodating possible challenges, reflecting best practices in pharmaceutical patenting.
- Companies should perform detailed freedom-to-operate and validity analyses, considering the densely populated Korean patent space.
- The patent’s longevity extends through the 2030s, emphasizing the importance of enforcement and strategic management.
- Cross-jurisdictional patent families will be crucial for global market protection and defensibility.
FAQs
-
What are the typical challenges faced when patenting pharmaceutical compounds like KR20150119871 in South Korea?
Prior art, especially existing chemical compounds and formulations, makes it crucial to craft claims that are both broad for coverage and specific enough to avoid invalidation.
-
How does South Korea’s patent law impact the enforcement of drug patents like KR20150119871?
South Korea’s rigorous patent system facilitates enforcement but also provides avenues for invalidity challenges; patent holders must actively monitor and defend their rights.
-
Can KR20150119871 be extended or supplemented with additional patents?
Yes. Companies often file continuations or divisional applications to broaden protection or cover new embodiments, ensuring ongoing IP protection.
-
What is the significance of patent claims related to drug delivery systems observed in similar patents?
They can provide additional layers of protection, especially for formulations that improve bioavailability or patient compliance.
-
How does KR20150119871 fit within the global pharmaceutical patent landscape?
It sets a foundation for international patent filings, supporting global expansion efforts and providing leverage in licensing negotiations.
References
- List of patent documents, legal analyses, and industry reports pertinent to KR20150119871.
- South Korea Intellectual Property Office (KIPO) database.
- Industry patent landscape analyses and reports.
Note: Exact claim language and detailed technical disclosures require review of the original patent document. This overview synthesizes typical patent claim strategies and landscape considerations pertinent to similar pharmaceutical patents in South Korea.
